MTOR and gastric cancer: Based on both the enrichment profile of preferentially active drugs as well as gene expression and signal transduction aberrations in c.1380delA CDH1 SB.mhdgc-1 gastric cancer cells, we selected the dual PI3K/mTOR inhibitor PI-103 and the topoisomerase II inhibitors etoposide and mitoxantrone as leads for further follow-up.